Induktionsbehandlung mit Nab-Paclitaxel / Gemcitabin zur Erstbehandlung von metastasiertem Pankreaskarzinom, gefolgt von abwechselnder Anwendung von Gemcitabin-Monotherapie und Nab-Paclitaxel / Gemcitabin oder fortgesetzter Anwendung von Nab-Paclitaxel / Gemcitabin: Eine randomisierte Phase-II-Studie
Progression-free survival (PFS) as time from randomization to objective tumor progression or death from any cause Overall response rate ([ORR]; according to RECISTv1.1) determined from first application of induction treatment Disease control rate ([DCR]; according to RECISTv1.1) determined from first application of induction treatment Quality of life (QoL) as determined with EORTC QLQ-C30 determined from randomization Safety variables: Type, incidence, and severity of adverse events according to NCI CTCAE version 4 with explicit consideration of any neurotoxicity Duration of treatment without toxicity leading to permanent discontinuation Functional assessment of neurotoxicity (with FACT taxane score)
